NAMI - National Alliance on Mental Illness Home | About NAMI | Contact Us | En Espanol  | Donate  
  Advanced Search  

Sign In
Register and Join
What's New
State & Local NAMIs
Advocate Magazine
NAMI Newsroom
NAMI Store
National Convention
Special Needs Estate Planning
NAMI Travel

Top Story

Print this page
Graphic Site
Log Out
 | Print this page | 

Metabolic Tests Ignored in Medicaid Patients

January 14, 2009

New analysis of more than 100,000 Medicaid patients suggests that while most psychiatrists are aware of the metabolic risks associated with second-generation antipsychotic medication, and the need to therefore monitor blood glucose and lipid levels, most patients are not screened.

Only approximately 25% of Medicaid patients received blood glucose level tests and 10% of patients had lipid levels tested.

The American Diabetes Association and American Psychiatric Association previously described the metabolic risks associated with second-generation antipsychotics and outlined a monitoring practice for patients. The protocol includes taking baseline assessment of personal/family history, weight, waist circumference, blood pressure, fasting glucose level and fasting lipid profile.


Copyright Date: 01/17/2010

Post a Comment, Share on Facebook

 | Print this page | 


Support NAMI to help millions of Americans who face mental illness every day.

Donate today

Speak Out

Inspire others with your message of hope. Show others they are not alone.

Share your story

Get Involved

Become an advocate. Register on to keep up with NAMI news and events.

Join NAMI Today
Home  |  myNAMI  |  About NAMI  |  Contact Us  |  Jobs  |  SiteMap

Copyright © 1996 - 2011 NAMI. All Rights Reserved.